Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway

Tomoka Takao, Hirotaka Masuda, Takashi Kajitani, Fumie Miki, Kaoru Miyazaki, Yushi Yoshimasa, Satomi Katakura, Shoko Tomisato, Sayaka Uchida, Hiroshi Uchida, Mamoru Tanaka, Tetsuo Maruyama

Open source

DOI: 10.1186/s13287-022-02888-y
Published: 2022-06-03
Container: Stem Cell Research & Therapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13287-022-02888-y,
  title = {Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway},
  author = {Tomoka Takao and Hirotaka Masuda and Takashi Kajitani and Fumie Miki and Kaoru Miyazaki and Yushi Yoshimasa and Satomi Katakura and Shoko Tomisato and Sayaka Uchida and Hiroshi Uchida and Mamoru Tanaka and Tetsuo Maruyama},
  year = {2022},
  journal = {Stem Cell Research \&amp; Therapy},
  doi = {10.1186/s13287-022-02888-y},
  url = {https://doi.org/10.1186/s13287-022-02888-y}
}

RIS

TY  - JOUR
TI  - Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway
AU  - Tomoka Takao
AU  - Hirotaka Masuda
AU  - Takashi Kajitani
AU  - Fumie Miki
AU  - Kaoru Miyazaki
AU  - Yushi Yoshimasa
AU  - Satomi Katakura
AU  - Shoko Tomisato
AU  - Sayaka Uchida
AU  - Hiroshi Uchida
AU  - Mamoru Tanaka
AU  - Tetsuo Maruyama
PY  - 2022
JO  - Stem Cell Research &amp; Therapy
DO  - 10.1186/s13287-022-02888-y
UR  - https://doi.org/10.1186/s13287-022-02888-y
ER  -

APA

Takao, T., Masuda, H., Kajitani, T., Miki, F., Miyazaki, K., Yoshimasa, Y., Katakura, S., Tomisato, S., Uchida, S., Uchida, H., Tanaka, M., & Maruyama, T. (2022). Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-022-02888-y

Source records

crossref · retrieved 2026-09-27T13:12:05.546Z